Analysts: Xtandi March-In Demands 'Noise,' 'Misguided'
This article was originally published in Scrip
Executive Summary
A demand by a group of lawmakers for the National Institutes of Health (NIH) to use its "march-in rights" authority as a way to bring down the US price of Medivation Inc.'s and Astellas Pharma Inc.'s prostate cancer drug Xtandi (enzalutamide) is simply "noise" and an action the agency is unlikely to take, analysts said on March 29.